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The Wilderness Medical Society convened an expert
panel to develop a set of evidence-based guidelines for
the prevention and treatment of North American pitviper
envenomations. We present a review of pertinent path-
ophysiology, discuss prevention measures, and therapeu-
tic management. Graded recommendations are made
regarding each treatment and its role in management.
These guidelines should assist in clinical decision mak-
ing, but a “cookbook” approach is often insufficient, as
each patient is unique and may respond differently to
therapeutics. Physicians must use their experience and
frequent clinical assessments to apply these recommen-
dations to their individual patients. Consultation with a
local toxicologist familiar with envenomations or poison
control center is recommended to assist in patient
management. These guidelines are for crotaline snakes
in the United States and Canada, and should not be
applied to other snakes species or geographic regions.
Methods
The expert panel was convened at the 2014 Annual
Winter Meeting of the Wilderness Medical Society in
Park City, Utah. Members were selected based on
clinical and research experience and interest in snakebites
and included members with specialties in emergency
medicine, surgery, toxicology/toxinology, wilderness med-
icine, herpetology, and evolutionary biology. Relevant
English language articles from 1965 to 2013 wereng author: Nicholas C. Kanaan, MD, 30 North 1900 East
, Room 1C026, Salt Lake City, UT 84132. (e-mail:
il.com).identified through the PubMed MEDLINE database
using search terms (antivenom, copperhead, cottonmouth,
crotalid, Crotalinae, crotaline, Crofab, digital dermotomy,
envenomation, FabAV, fasciotomy, first aid, pitviper,
prevention, rattlesnake, snakebite, treatment, and Viper-
idae). Studies in these categories were reviewed and level
of evidence was assessed. The panel used a modified
Delphi consensus approach to develop recommendations
graded based on the quality of supporting evidence and
balance between the benefits versus risks and burdens for
each modality according to criteria stipulated by the
American College of Chest Physicians (Table 1).1Section 1: Characteristics
VENOMOUS SNAKES IN THE UNITED STATES
AND CANADA
The taxonomic family Viperidae contains the Old World
taxa (subfamily Viperinae) and the Old and New World
pitvipers (Crotalinae), which are venomous snakes with
long folding fangs. Crotalinae are pitvipers with heat-
sensing facial (loreal) pits, including the North American
rattlesnakes (genera Crotalus and Sistrurus) and cotton-
mouths and copperheads (genus Agkistrodon). Crotalus
contains almost all rattlesnakes and includes the larger,
widely distributed, and more dangerous species. Sistru-
rus includes only 2 small species north of Mexico: the
pigmy rattlesnake (Sistrurus miliarius) and the massa-
sauga (Sistrurus catenatus). Cottonmouths or water
moccasins (Agkistrodon piscivorus) and copperheads
(Agkistrodon contortrix) are similar to rattlesnakes but
lack a rattle, having tapered, pointed tails instead. All of
these pitvipers are generally heavy-bodied snakes with
Table 1. American College of Chest Physicians classification scheme for grading evidence in clinical guidelines
Grade Description Benefits vs risks and burdens Quality of supporting evidence
1A Strong recommendation, high-
quality evidence
Benefits clearly outweigh risk and







Benefits clearly outweigh risk and
burdens, or vice versa
RCTs with important limitations
or exceptionally strong evidence
from observational studies
1C Strong recommendation, low-
quality evidence
Benefits appear to outweigh risk
and burdens or vice versa
Observational studies or case
series
2A Weak recommendation, high-
quality evidence






2B Weak recommendation, moderate-
quality evidence
Benefits closely balanced with
risks and burdens
RCTs with important limitations
or exceptionally strong evidence
from observational studies
2C Weak recommendation, low-
quality evidence
Uncertainty in estimates of
benefits, risks, and burdens;
benefits, risks, and burdens may
be closely balanced
Observational studies or case
series
RCT, randomized controlled trial.
WMS Practice Guidelines for Pitviper Envenomations 473triangular heads, vertically elliptical pupils, keeled dorsal
scales, and a single row of subcaudal scales. Although
these traits can be found in various nonvenomous
snakes, the specific combination of keeled dorsal scales
and undivided subcaudal scales is diagnostic for pit-
vipers in the United States and Canada.2 The rattle is
unique to rattlesnakes.
Coral snakes are the only other major venomous
snakes naturally found in the United States and Canada
and belong to the family Elapidae, which also includes
cobras, mambas, and kraits. They are slender and
identified by the order of their black, red, and yellow
(or white) body rings (although they rarely can be
melanistic) and do not possess any of the previously
mentioned pitviper traits.2 Because the management of
coral snake envenomation differs from pitvipers, their
management is not included in these guidelines.
Field guides and other publications list nearly a
hundred subspecies of “dangerous” North American
snakes; however, the taxonomy of these snakes remains
incompletely defined as ongoing genetic analyses are im-
proving species characterization.3 Some experts suggest
the elimination of many subspecific designations alto-
gether.4 Clinically, identification to the species or
subspecies level is usually unnecessary for guiding
treatment—with the exception of Mohave (Crotalus
scutulatus), timber (Crotalus horridus), and Southern
Pacific rattlesnakes (Crotalus oreganus helleri), amongother taxa that may produce venoms containing potent
Mohave or similar presynaptic neurotoxins. Snakebites
with this toxin require management that differs from the
majority of crotaline envenomations in the United States.5,6
Knowledge of pitviper geographic distributions can
help identify a snake (Figure). A picture of the snake can
also help with identification by an expert at a later time;
however, trying to kill or capture the snake is not re-
commended as it could lead to a second patient requiring
treatment.7 If positive identification of a nonvenomous
snake by an expert is made, no evacuation is necessary.
Snakes are poikilothermic and tend to seek under-
ground shelter during temperature extremes. Therefore,
wild snakes are usually not a threat during cold weather
unless their shelter is breached. Field and laboratory
studies of temperate pitvipers indicate that they are more
active with body temperatures between approximately
25ºC and 30oC (77ºF–86oF).8–10 Snake body temper-
atures are better correlated with substrate temperature
than air temperature, and unshaded substrate temperature
can be much hotter than the air on warm sunny days.11VENOM PROFILES
Some pitviper venoms are known to contain more than 100
different proteins and peptides that produce toxic effects in
prey and envenomated humans.12,13 The toxic components
of snake venom vary greatly and are naturally selected in
Figure. Three common pitvipers in the United States and Canada and their geographic range. From top to bottom: Western rattlesnake (Crotalus
oreganus) and geographic range of Crotalus and Sistrurus; Cottonmouth (Agkistrodon piscivorus) and geographic range of A piscivorus;
Copperhead (Agkistrodon contortrix) and geographic range of A contortrix.
Kanaan et al474response to prey susceptibility.14,15 These toxic constituents
are known to vary considerably between species,16
geographically within species,17–19 ontogenetically within
individuals,20 and even between siblings.21,22 The genes
expressing toxins undergo more rapid evolution than
nontoxin-related genes.16 Given these variations in venom
composition, it is not possible to predict the specific
frequency of various venom components. Despite thislimitation, important generalizations can be made based on
genetic and molecular analysis of venom supported by
clinical experience and may inform the clinical course.20
Ontogenetic variation in snake venoms also appears to
be correlated with changes in diet as young snakes
mature, often switching from predation of lizards and
frogs to a diet consisting primarily of small mam-
mals.23,24 That may be related to the widespread myth
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because they have not yet learned to meter their venom.
Regardless of venom metering, small snakes have small
heads and venom glands and simply do not have the
volume of venom available in larger snakes, as is borne
out by venom yields in laboratories that produce venom
for pharmaceutical and research use: the average yield of
100-cm rattlesnakes is 1100 mg (dry mass) compared
with 9 mg from 30-cm juveniles,25 a difference of 2
orders of magnitude. That is consistent with clinical ex-
perience; namely, bites by medium and large rattlesnakes
have been shown to produce mean snakebite severity
scores that are almost double those produced by small
rattlesnakes.26Section 2: Epidemiology and Prevention
Snakebites are estimated to lead to as many as 9000
emergency department visits annually in the United States.
Venomous species account for approximately one third of
these visits, almost all of which are pitviper bites.27
Accurate snakebite statistics are difficult to assemble in
the United States. Nonfatal bites by venomous species are
underreported by epidemiological databases. Poison centers
are not consulted on all bites, and many bites are never
reported beyond a primary treating facility. Finally, an
unknown but likely significant number of snakebite patients
never seek medical treatment, especially if alarming
symptoms fail to develop. Many experts continue to rely
somewhat on the statistics published in 1966 by Dr
Parrish,28 based on his unprecedented survey returned by
more than 5000 hospitals and 27,000 physicians in the
United States. He estimated that approximately 6680
persons per year were treated for venomous snakebite in
1958 and 1959.28 Based on the work of Parrish and more
current, albeit less robust data, recent investigators have
estimated the incidence of venomous snakebite in the
United States at roughly 7000 to 8000 per year,29 with
annual fatalities averaging 5.2 between 1991 and 200130
and 7.4 between 1999 and 2007.31 According to recent
data from the American Association of Poison Control
Centers (AAPCC), there were 6919 snakebites reported
to poison centers in 2012, 4052 of which were pitviper
envenomations. More than half (57%) of pitviper
envenomations in this dataset resulted in moderate or
major outcomes, as defined by the AAPCC, and 1 bite
(by a rattlesnake) was fatal.32 These data are based on
voluntary reporting to poison control centers, and hence are
certain to underreport the problem.
The majority of crotaline envenomations occur during
intentional interaction with the snake, as opposed to an
unintentional exposure to an unseen threat.33,34 Most
snakebite patients are male, with white men 25 to 34years old being at greatest risk of life-threatening
envenomations.35 Intentional interactions may be asso-
ciated with alcohol or drug intoxication33–36 and typi-
cally occur when people try to catch, kill, or interfere
with a wild snake, as well as when handling or caring for
captive snakes. Moreover, caution must be exhibited
when handling a dead snake or detached head as they
may have intact bite reflexes.29,37 Knowledge of snake
habits and appropriate avoidance measures, in addition
to not deliberately antagonizing these animals, offers the
most significant protection from unwanted exposure.
Most studies indicate that the majority of bites occur
on the upper extremities, fewer on the lower extremities,
and rarely on the face, neck, or trunk.27,34 Bites from
unintentional encounters are predominantly on the lower
extremities, whereas those resulting from intentional
interaction are mainly on the hands and arms.27 Certain
protective clothing such as leather or heavy boots offers
a protective barrier against envenomation, and denim
may reduce the amount of venom by two thirds.38,39
Pitvipers are almost exclusively ambush predators40
and seek out locations where they are likely to encounter
prey (mostly rodents and other small mammals), then
coil and wait motionless for prey to enter within strike
range.40,41 In locations with harsh winters, snakes must
migrate between winter dens and summer foraging areas,
increasing the probability of human interaction.42,43 The
kinematics of the strike and venom injection are usually
different between defensive and predatory strikes,44 and
almost all bites to humans are defensive. As a result,
research about predatory behavior is not necessarily
applicable to human snakebites. The exception are
bites by long-term captives, as these animals often lose
fear of humans and associate any cage disturbance with
feeding. Emergency departments presented with patients
bitten by captive (and frequently exotic) snakes must
reliably identify the snake and locate the appropriate
antivenom.45 A small but significant number of persons
privately keep venomous exotic snakes—often illegally.
These snakes may be misidentified or the species name
withheld on account of potential legal consequences.
When exotic antivenom is needed, it frequently requires
collaboration with a zoo that keeps the same species. An
exotic antivenom database is maintained for this purpose
and can be accessed through local poison control centers.
Section 3: Field Management
INITIAL MANAGEMENT AND FIRST AID
A priority after a snakebite is to avoid another bite, either
to the same patient or to another. Patients should move
away from the snake. The patient should be calmed, as
fatalities are rare and serious sequelae are usually
Kanaan et al476preventable. A good photograph, carefully taken from a
safe distance (ie, equal to more than the length of the
snake), can sometimes be transmitted by cell phone to an
expert and may be valuable later for identification. If in
doubt, determining whether the biting snake is a venom-
ous species can make the difference between simple
superficial wound care and a potentially hazardous and
expensive evacuation.
There is nothing that can be done in the field to
significantly alter the outcome of a serious snakebite, and
field first aid should not delay rapid transfer to a facility
capable of safely administering antivenom.46 The degree
of envenomation cannot be quickly determined with
confidence; therefore, any bite by a venomous species
must be considered a medical emergency and evaluated
by a physician without delay. While en route or waiting
for evacuation, first aid and wound care can be admini-
stered.
Time and date of the snakebite should be noted, either
on the patient or in an incident report. Circumference of
bitten appendage should be measured above and below
the snakebite for later comparison and determination of
subsequent swelling.47,48 The leading edge of erythema
should be marked for comparison. Jewelry or constric-
tive clothing near the bite should be removed or cut to
avoid constriction with subsequent swelling. (Recom-
mendation grade: 1C)
Snakebites should be approached in a manner similar
to that for any other puncture wound or laceration.
Without delaying transport, the wound should be quickly
cleaned in standard fashion (soap and running water,
high-pressure irrigation or an antiseptic solution or both)
and a sterile dressing applied to protect the wound.49
(Recommendation grade: 1C)
There have been no studies directly assessing immo-
bilization alone for the improvement of snakebite out-
comes. Limiting movement of the affected area by
immobilization with splinting techniques (without com-
pression) may benefit the patient, although no rigorous
trials have validated this practice. Depending on the
evacuation needs, the affected area should be maintained
at the level of the heart: raising it above the heart can
cause increased systemic spread of venom, whereas
lowering it may lead to increased swelling and local
venom activity. However, this practice has not been
proved with evidence or clinical trials. Furthermore, the
limb and joints should be kept in a functional position
in case they swell or the joints become immobile.50,51
(Recommendation grade: 2C)
Any initial symptoms should be clearly noted in a
field report. Local symptoms should be noted and
monitored for progression. Local tissue effects from
hemotoxins or vasculotoxins can cause significanterythema, swelling, and tenderness at the envenomation
site and can spread proximally and distally. Local tissue
effects are the most common physical manifestations of
pitviper envenomations and occur in more than 90% of
patients with medically significant envenomations.25
(Recommendation grade: 1C)
Systemic symptoms including hypotension, bleeding,
angioedema, vomiting, and neurotoxicity indicate more
severe envenomation.52 Hematologic effects are multi-
factorial and include the degradation of fibrinogen and
platelet aggregation or destruction. Although the
majority of patients do not develop medically signi-
ficant bleeding, the patient should be carefully examined
for petechiae, ecchymosis, gingival bleeding, epistaxis,
retinal hemorrhage, or signs of more serious hemor-
rhage (ie, intracranial or intra-abdominal).53 Vomiting
can also arise from autonomic response to fear and
anxiety, and may be misleading. Hypotension can result
from vasodilatation and third-spacing. The most com-
mon neurotoxic effects are from Mohave rattlesnake
(C scutulatus) and Southern Pacific rattlesnake (C helleri),
but are much less common in other US rattlesnake
species.54 All snakebite patients, especially those with
local or systemic symptoms, should be transported im-
mediately to a hospital for evaluation and monitoring for
progression (Table 2). (Recommendation grade: 1C)
Unfortunately, there are many myths associated with
the field care of snake envenomations, some of which
can be harmful to the patient. Despite a lack of evidence,
many of these techniques have permeated popular
culture and historical medical literature, and therefore
they are often erroneously applied. The following
techniques are of no benefit or are potentially harmful
to the patient.
Oral suction
One study and review article showed that mouth or
mechanical suction is not successful at removing venom
in a “mock venom” human model, and the 0.04% to 2%
of venom load extracted was clinically insignificant.55
Furthermore, oral suction can introduce bacteria into the
wound and increase the potential for superinfection or
abscess formation. Finally, oral suction may pose a risk
to the caregiver by absorption of venom through the oral
mucosa.56 (Not recommended)
Mechanical suction
An experimental model showed that mechanical suction
devices can increase localized tissue damage around the
wound in the shape of the device, causing tissue necrosis
and sloughing, resulting in tissue loss that prolonged
healing by weeks.57–59 (Not recommended)
Table 2. Local, systemic, hematologic, and neurologic signs and symptoms of snakebite envenomation
Local Systemic Hematologic Neurologic
Pain Tachycardia* Anemia Diplopia
Localized bleeding Dyspnea* Thrombocytopenia Perioral paresthesias or
metallic taste
Erythema Chest pain Petechiae Numbness/tingling
(widespread)
Edema Nausea or vomiting* Gingival bleeding Fasciculations (widespread)
Ecchymosis Hypotension Epistaxis Altered mental status
Blistering Angioedema Retinal hemorrhage Cranial nerve dysfunction,
especially ptosis (Mohave
toxin)








n Can be from envenomation or autonomic responses to pain and anxiety, therefore not used as a sole indicator of systemic signs of
envenomation.
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Laceration or bleeding the bite site to enlarge the wound
to increase blood flow often results in increased tissue
damage and local irritation and is without any proven
benefit.60 (Not recommended)
Electricity or electrotherapy
At one time, it was theorized that electrical current may
denature snake venom, but research demonstrated that
electrotherapy is not useful for snakebite treatment and is
harmful to the patient.61–63 (Not recommended)
Cryotherapy or cooling
Cryotherapy with ice or other cooling techniques is
thought to reduce the spread of the snake venom;
however, this technique has no proven benefit, and in
extreme cases can result in increased localized tissue
injury.64–66 (Not recommended)
Tourniquet placement
Tourniquets (either venous or arterial occluding tourniquets)
can lead to ischemia and gangrene, which can result in a
higher amputation frequency or antivenom requirements,
and no studies have conclusively demonstrated tourniquets
improve patient outcomes.46,67,68 (Not recommended)
Pressure bandaging
Clinical evidence for pressure bandaging with elastic or
cohesive bandaging is limited, and it does not appear tohave any benefit in crotaline envenomations. Pressure
bandaging is thought to restrict the blood flow and
progression of venom to systemic circulation by reduc-
ing lymphatic and venous return. One study using a
porcine model with a lethal dose of venom showed
pressure immobilization increased intracompartmental
pressure after envenomation and delayed mortality.69
Only when treating life-threatening snakebites contain-
ing neurotoxic venom (such as Australian elapids) does
evidence support containing the venom with pressure
bandaging.70 These results have not been replicated in
the United States and Canada where crotaline venom
causes more localized tissue damage, and pressure
bandaging may instead increase the severity of tissue
damage; 1 animal study demonstrated lethal hy-
perkalemia when the pressure wrap was removed.71
Furthermore, 2 studies indicated that physicians and
laypeople rarely apply pressure bandaging correctly,72,73
and a third showed that even after training, practitioners
were still unsuccessful at effective immobilization in cases
of simulated snakebites.74 Pressure bandaging has not
been proven beneficial in studies and case series involving
crotaline envenomations.75,76 (Not recommended)THE DRY BITE
Venomous snakes may also fail to deliver venom in an
event commonly referred to as a dry bite that may occur
in 25% or more of crotaline bites.25,77 Duration of fang
contact also affects the amount of venom injected in both
predatory and defensive situations, with venom quanti-
ties from defensive bites (eg, to humans) being more
Kanaan et al478variable and often larger than predatory bites.78,79 It may
be difficult to initially determine whether a bite was dry
or if venom was injected. A dry bite should never be
assumed, and serial observations and laboratory tests
should be performed as indicated to monitor the possible
development of envenoming. If there are fang marks and
a positive identification of a pitviper, one must assume
there is associated envenomation and seek medical
attention immediately because delaying care increases
morbidity and mortality. If evacuation is difficult or
prolonged, the absence of local or systemic symptoms 8
hours after the bite may indicate a dry bite. (Recom-
mendation grade: 1C)
EVACUATION CONSIDERATIONS
As a general rule, all venomous snakebites should be
evacuated and transported to the nearest emergency
department. Rapid transport to an emergency department
allows for life- or limb-saving interventions. For the
caregiver familiar with envenomations, a positive iden-
tification of a nonvenomous snake would not necessitate
evacuation; however, identification must be certain.
Even a knowledgeable caregiver may not be able to
predict the amount of envenomation from a snakebite or
potential sequelae, and therefore observation for the sake
of risk stratification is not recommended. [Recommen-
dation grade: 2C]
Every effort should be made to evacuate snakebite
patients; however, if the patient is in a remote location
with a difficult evacuation, further considerations must
be weighed, including patient and rescuer safety, like-
lihood of successful evacuation, and availability of
resources required to carry out the evacuation. Evacuat-
ing to a health facility without access to antivenom may
be of little benefit to the patient. The nearest healthcare
facility should be contacted ahead of time, and if
antivenom is unavailable, it may be sent from another
facility or the patient’s immediate transport to a different
facility arranged. This process can also be coordinated
by contacting poison control directly. (Recommendation
grade: 1C)
Section 4: Emergency Department Management
INITIAL PATIENT ASSESSMENT
On arrival to the emergency department, snakebite
patients should be rapidly assessed, including airway,
breathing, and circulation. After initial assessment and
vital signs, the patient should be placed on continuous
cardiac, blood pressure, and pulse oximetry monitoring.
A thorough history including the time of the bite and
signs or symptoms of envenomation should be takenfrom the patient or bystanders. It is important to remove
constrictive clothing or jewelry because of the risk of
increasing swelling.7 The leading edge of tenderness,
erythema, and swelling should be marked and limb circum-
ference above and below the envenomation measured for
future comparison. That should be repeated every 15 to 30
minutes until local tissue effects have stabilized. (Recom-
mendation grade: 1C)
LOCAL WOUND CARE AND ANTIBIOTICS
Anaerobic and aerobic bacteria can be introduced by the
snake’s fangs during the bite.80 Despite this inoculation,
wound infections occur in only 3% of pitviper bites.81 A
prospective trial compared prophylactic antibiotic
treatment to none after pitviper envenomation and
found no significant differences in rates of infection
between the groups.82 One analysis noted 0% infection
rate after crotaline envenomation and prophylactic
antibiotics.83 Chloramphenicol failed to reduce the
frequency of abscess formation complicating pitviper
snakebites in a randomized controlled trial.84 Based on
current evidence, prophylactic antibiotics are not recom-
mended, and antibiotics should only be administered if
signs of infection develop, such as purulence (other signs
of infection may be obscured by local tissue changes
caused by venom). (Recommendation grade: 1C)
Any significant open wounds should be treated with
moist dressings changed twice daily, and large debrided
areas treated with negative pressure dressings.49 Early
active and passive physical therapy with range of motion
and occupational therapy is recommended, especially for
hand and digit bites to avoid stiffness and long-term
dysfunction.85 (Recommendation grade: 1C)
Opioids are preferred for pain control. Aspirin and
nonsteroidal anti-inflammatory drugs are relatively con-
traindicated owing to risks of increased bleeding, platelet
dysfunction, and potential for prerenal effects in patients
with rhabdomyolysis.50,86,87 (Recommendation grade:
1C)
Although there are no reported cases of tetanus
associated with snakebites, patients should receive teta-
nus immunization according to standard recommenda-
tions from the Centers for Disease Control and
Prevention.88 Administration of tetanus immunization
after reversing coagulopathy will minimize bleeding
from injection sites. (Recommendation grade: 1C)
DIAGNOSTIC AND LABORATORY ASSESSMENT
If envenomation is suspected, intravenous access should
be obtained in an unaffected extremity and initial
laboratory studies performed: complete blood count
(CBC) with platelets, basic metabolic panel, liver
Table 3. Laboratory and diagnostic testing for snakebite evaluation
Study Rational*
CBC Evaluate for anemia and thrombocytopenia
BMP Evaluate electrolytes and renal function for rhabdomyolysis
LFT Evaluate liver enzymes for hepatic dysfunction
PT/INR, PTT Evaluate for coagulopathy (INR is most useful)
Fibrinogen Most specific for coagulopathy—important to obtain measured (not calculated) level
D-dimer More sensitive for coagulopathy
Urinalysis Hemoglobin in absence of red blood cells or presence of myoglobin indicates rhabdomyolysis
TCK Evaluate for rhabdomyolysis
Troponin Evaluation of chest pain
ECG Evaluation of chest pain
Chest radiograph Evaluation of chest pain or shortness of breath
Type and screen Obtain early, though rarely required as coagulopathy is managed with antivenom
CT brain (noncontrast) Evaluation of neurological findings suggesting hemorrhagic cerebrovascular accident
CT abdomen or FAST US Evaluation of abdominal pain and distention or concern for intra-abdominal bleeding
n Any abnormal results or changes in clinical condition warrant re-evaluation of laboratory studies.
CBC, complete blood count with platelets; BMP, basic metabolic panel; LFT, liver function tests; PT/INR, prothrombin time/international
normalized ratio; PTT, partial thromboplastin time; TCK, total creatine kinase; ECG, electrocardiogram; CT, computed tomography; FAST,
focused assessment with sonography in trauma; US, ultrasonography.
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ratio (PT/INR), partial thromboplastin time, fibrinogen,
d-dimer, total creatine kinase, and urinalysis (Table 3).
These studies provide baseline laboratory characteristics
for serial evaluation and help diagnose anemia, thrombo-
cytopenia, coagulopathies, and rhabdomyolysis. For
critically ill patients with complaints of chest pain or
shortness of breath, further diagnostic studies include a
12-lead electrocardiogram, chest radiograph, and tropo-
nin. If a patient presents with proteinuria, testing for
myoglobinuria and microscopic hematuria should be
performed. If myoglobinuria or severe muscle swelling
is present, serial total creatine kinase assays are indicated
to evaluate for rhabdomyolysis. Providers should per-
form serial comprehensive neurological examinations
and order a noncontrast computed tomography scan of
the brain if any deficit is identified or there is concern for
hemorrhagic cerebrovascular accident. For patients with
a potentially worrisome abdominal examination, pro-
viders should consider further imaging with abdominal
ultrasound or computed tomography to assess for possi-
ble intra-abdominal bleeding.50 (Recommendation grade:
1B)
Serial laboratory studies including CBC, basic meta-
bolic panel, PT/INR, d-dimer, total creatine kinase, and
fibrinogen should be obtained for all patients with
pitviper bites. For suspected dry bites, patients should
be observed for a minimum of 8 hours and undergo
repeated laboratory studies before discharge, if vital
signs are normal. For minor envenomations, patients
should be observed for 12 to 24 hours and have repeatlaboratory studies every 4 to 6 hours. Patients with
moderate to severe envenomations should receive anti-
venom, be admitted to the hospital, and have repeat
laboratory studies within 4 hours of the initial set.50
(Recommendation grade: 1C)INDICATION FOR ANTIVENOM
Antivenom and supportive care are the mainstay for
crotaline envenomation management. The ovine-derived
Crotalidae polyvalent immune Fab antivenom (FabAV)
was approved by the US Food and Drug Administration
in 2000 and causes fewer adverse reactions than the
previous equine-derived polyvalent product. FabAV
works by binding to and neutralizing crotaline venom
in the intravascular space and also diffuses into the
interstitium arresting progression of local tissue injury.
Whereas older resources use a snakebite grading scale to
stratify crotaline envenomation, it is now recommended
to administer antivenom in any patient with progressive
signs or symptoms after a crotaline snakebite.50
Patients with a dry bite or who have not been bitten by a
pitviper should not receive antivenom. Patients with minor
envenomation, defined as swelling and localized pain at
the envenomation site, should be closely observed and not
be given antivenom unless local tissue effects progress.50
Snakebites to high-risk anatomical sites (ie, hands, joints,
or face) may necessitate a more conservative approach,
lowering the threshold for antivenom administration as
localized tissue effects can have more severe and poten-
tially long-term sequelae.89 (Recommendation grade: 1C)
Kanaan et al480Patients with progressive local tissue findings or any
systemic toxicity (signs, symptoms, or acute laboratory
abnormalities) should receive antivenom. Progression
after pitviper envenomation is defined as worsening of
local tissue injury (Z2 cm of erythema expansion),
systemic symptoms, or abnormal laboratory results.
Moderate envenomation includes bites with severe local
pain, worsening edema, mild to moderate systemic
symptoms that are not life threatening, and abnormal
coagulation tests without signs of bleeding. Severe
envenomation includes bites with significant swelling
and pain, systemic symptoms that are life threatening,
and abnormal coagulation tests with serious bleeding.
Common systemic symptoms include hypotension, sys-
temic bleeding, or neurotoxicity. Various symptoms of
neurotoxicity and myotoxicity include oral paresthesias,
muscle fasciculations, altered mental status, or seiz-
ures.90 For patients receiving antivenom, providers
should contact a medical toxinologist or poison control
center (United States (800)222-1222, British Columbia
(800)567-8911, Ontario (800)268-9017, Québec (800)
463-5060). (Recommendation grade: 1A)ANTIVENOM ADMINISTRATION
The initial dose of FabAV is 4 to 6 vials, with each vial
reconstituted in 25 mL 0.9% sterile saline and gently
rotated 180 degrees back and forth to dissolve the
powder into solution. Although the manufacturer recom-
mends reconstituting with 18 mL, 25 mL is associated
with decreased dissolution times.91 Once reconstituted,
the 4 to 6 vials should be further diluted with normal
saline to a volume of 250 mL. Then 25 mL should be
infused intravenously over the first 10 minutes, and if
there is no allergic reaction, the remaining infusion
should be given over 1 hour.92 Dosing is based on the
amount of venom and not the weight of the patient, and
therefore remains the same for children. For infants
weighing less than 10 kg in whom fluid overload is a
concern, the antivenom can be mixed in a smaller
volume to approximate a 20 mL/kg bolus.93 (Recommen-
dation grade: 1A)
There are no absolute contraindications to FabAV
because the benefits of antivenom outweigh the risks of
reactions from allergy to FabAV or hypersensitivity to
papain or papaya extracts—papain is used to cleave the
whole antibody into Fab and Fc segments, and a small
inactive amount may be left in the antivenom.94 In these
cases, patients should be pretreated for allergic reactions
and monitored closely (see Section 6). (Recommendation
grade: 1B)
It is important to obtain initial and prompt control of
crotaline envenomations. As many as 88% of patientstreated with antivenom achieve initial control, which is
defined as no further tissue swelling or ecchymosis,
improvement of vital signs, improvement of systemic
symptoms, and stabilized coagulopathy.92 In addition to
reassessing vital signs and wound site every 15 to 30
minutes, repeat laboratory studies with CBC, PT/INR,
partial thromboplastin time, and fibrinogen should be
obtained within 1 hour of antivenom administration to
assess response. If there is progression of local or
systemic symptoms or worsening laboratory
abnormalities within the first hour, 4 to 6 more vials
should be given to gain initial control.95 According to
prior studies, 4 to 18 vials of FabAV may be required to
achieve initial control.92 (Recommendation grade: 1A)
All patients receiving antivenom should be admitted to
the hospital for further observation, maintenance antive-
nom dosing, and repeat laboratory testing until abnormal-
ities resolve. Manufacturer recommended maintenance
dosing includes 2 vials of antivenom every 6 hours for
3 consecutive doses. The treating physician may elect to
deviate from the redosing schedule based on the patient’s
response and clinical course.96 Patients should be moni-
tored closely for any recurrence of signs and symptoms
that warrant additional antivenom. Clinical deterioration
should prompt repeat doses of antivenom and timely
toxinologist or poison control center consultation.92
(Recommendation grade: 1B)DISPOSITION
Dry bites that show no progression beyond the simple
wound should be monitored for a minimum of 8 hours,
with laboratory studies repeated during observation to
monitor for possible delayed onset of venom effects.
Patients who present late (48 hours from their initial
bite) should be observed for 2 to 4 hours with laboratory
evaluation. Patients safe for discharge should have
normal vital signs and not have abnormalities or
concerning trends in laboratory studies. (Recommenda-
tion grade: 1C)
Patients with a minor envenomation (characterized by
local pain, mild edema, no signs of systemic toxicity,
and normal laboratory studies) should be observed for
approximately 12 to 24 hours and should also have
repeat laboratory studies before discharge.50 Other
factors influencing this observation time are patient
age, comorbidities, bite location, and healthcare access
(Table 4). (Recommendation grade: 1C)
For patients who are admitted and receive antivenom,
discharge information should include precautions on
serum sickness and delayed coagulopathy. Provide clear
information to return immediately for any signs of
envenomation progression. Discharged patients should
Table 4. Emergency medicine care of crotaline envenomations
Envenomation Observation Laboratory Studies Treatment




12–24 hours Initial laboratory studies; repeat
laboratory studies† every 4–6
hours and before discharge
Consider antivenom only if





Admit Initial laboratory studies; repeat





with systemic signs and/or
end-organ damage
Admit Initial laboratory studies; repeat




n Initial laboratory studies include complete blood count with platelets, basic metabolic panel, liver function tests, prothrombin time/
international normalized ratio, partial thromboplastin time, total creatine kinase, fibrinogen, urinalysis.
† Repeat labs include complete blood count with platelets, prothrombin time/international normalized ratio, and fibrinogen.
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gen) as an outpatient 2 to 3 days and 5 to 7 days after
their last antivenom dose to evaluate for delayed onset or
recurrent coagulopathy.54,97 They should also avoid
contact sports, dental extractions, tattoos/piercings, and
elective surgery for as long as 2 weeks. (Recommenda-
tion grade: 1B)
Section 5: Wound Management
Wounds after pitviper envenomation can be extensive
and may require acute and chronic management. Com-
mon components of crotaline venom cause edema,
hemorrhage, and sometimes necrosis at the site of
envenomation. With the widespread availability of anti-
venom, surgical intervention in the acute management of
snakebites is rarely required.66
DEBRIDEMENT
The vast majority of patients with crotaline bites recover
without the need for surgery. Occasionally, severe
Crotalus spp envenomations require surgical interven-
tion for wound debridement, whereas copperheads rarely
produce wounds requiring debridement.98 Historically,
aggressive surgery was incorrectly advocated for the
evaluation of injury, pain relief, compartment release,
and prevention of further tissue necrosis.99 In a series of
54 patients, conservative excision of ecchymotic tissue
was performed, with a complication rate significantly
higher than for nonsurgical management.100 Histological
evaluation of debrided tissue indicates live muscle
fibers interspersed with necrotic fibers, which could
recover.101,102 Given the complications associated with
surgery and improvements in the pharmacological treat-
ment of snakebites, early surgery is contraindicated.
Excision should not be routinely performed; however,necrotic tissue and hemorrhagic blisters may benefit
from debridement 3 to 5 days after injury, according to
generally accepted surgical principles.103 If secondary
infection develops, more extensive debridement or
antibiotic administration or both may be necessary.
(Recommendation grade: 1B)COMPARTMENT SYNDROME: FASCIOTOMY
AND DIGITAL DERMOTOMY
True compartment syndrome is a rare complication of
snakebites; however, it can lead to permanent disability
if there is a delay in diagnosis. The diagnosis of
compartment syndrome may be difficult because the
primary signs and symptoms are similar to that of
crotaline envenomations, including pain on passive
flexion and a tense extremity. The pathophysiology of
pitviper envenomation is different from that of compart-
ment syndrome as it is caused by superficial edema and
inflammation in the subcutaneous tissues rather than
subfascial spaces. In cases in which venom is deposited
within a muscle compartment, however, administration
of antivenom can prevent and treat compartment syn-
drome.66 In general, fasciotomy is rarely indicated and
generally discouraged, favoring antivenom administered
for reduction of intracompartmental pressure.103–106 An
experimental study of rabbits found antivenom for the
preservation of muscle function to be superior to both
fasciotomy alone and the combination of antivenom and
fasciotomy.102 In a series of 550 patients with snake-
bites, no patient needed fasciotomy,80 and a second
review found only 2 of 1257 reported cases underwent
fasciotomy.101 (Recommendation grade: 1B)
Serial examinations should be performed for 36 hours,
at which point swelling is maximal. If concern arises for
developing compartment syndrome, as in cases of severe
Kanaan et al482swelling and edema that persists after appropriate
administration of antivenom or development of suspi-
cious clinical findings (worsening pain, paresthesias,
pallor, etc), intracompartmental pressures should be
objectively measured. If the pressures exceed 35 to 40
mm Hg, then a presumptive diagnosis of compartment
syndrome should be made and appropriate surgical
consultation obtained.107 Although there is no uniform
consensus for pressures defining compartment syndrome,
clinical examination and serial pressure measurements
should be carefully assessed if the diagnosis is
entertained. Antivenom should be redosed (4–6 vials)
and the extremity closely monitored with neurovascular
examination and repeat pressure measurements. Early
and aggressive use of antivenom almost always pre-
cludes the need for fasciotomy; however, in the rare
patient who fails to respond, the decision to perform a
fasciotomy should be made by a surgeon within 6 hours
of signs of neurovascular compromise existing in the
face of elevated pressures despite appropriate admini-
stration of antivenom.66 (Recommendation grade: 1C)
The fingers and toes, because of their small diameter,
have limited space to swell. Digit envenomation has
been reported for as many as 21% of snakebites.107
There is no accurate way to directly measure pressures in
the digit; however, a tense, pale, insensate digit with
poor capillary refill would increase clinical suspicion of
digital compartment syndrome. Decision to perform
digital dermotomy must be based on neurovascular
examination with the aid of digital Doppler ultra-
sound.66 If digital dermotomy is indicated, a longi-
tudinal incision is made through the skin only from the
web space to the mid distal phalanx and can be done
under local anesthesia. Similar to fasciotomy, digital
dermotomy is rarely required. (Recommendation grade:
1C)
Section 6: Unique Populations
PREGNANT WOMEN
Pregnant women with crotaline envenomations should be
managed in close collaboration with an obstetrician.
Snakebite envenomations may lead to increased morbid-
ity to the fetus, and as many as 20% of documented
envenomations in pregnancy have associated fetal death
(with or without antivenom treatment). There have been
no reported adverse reactions to antivenom in the mother
or fetus108; however, owing to envenomation, the fetus is
at higher risk to coagulopathy-related complications such
as placental abruption.109 Therefore, snakebite patients
who are pregnant should receive antivenom as indicated
and fetal assessment or monitoring.110 (Recommendation
grade: 1C)PEDIATRIC PATIENTS
Pediatric snakebite patients should receive the same dose
of antivenom as an adult. The antivenom counteracts
snake venom and is dosed according to the amount of
venom injected, not patient body weight. Antivenom has
been shown to be safe to use in pediatric and infant
populations.93,111–115 (Recommendation grade: 1B)
ALLERGIC OR ANAPHYLACTIC REACTIONS
Antivenom-induced hypersensitivity reactions and serum
sickness occur in approximately 8% and 13%, respec-
tively, of patients treated with FabAV.116 Some can be
severe, and providers should be prepared to treat with
epinephrine, steroids, antihistamines, or emergency
airway management.7 Once the allergic reaction is
controlled, reversing the effects of venom remains para-
mount; therefore, physicians should resume slow
administration of the remaining antivenom (potential
benefit may be gained by further diluting to 1000 mL
instead of the original 250 mL). (Recommendation
grade: 1C)
Pretreatment with promethazine, hydrocortisone, or
prednisone was not shown in a randomized controlled
study to decrease adverse reactions to antivenom.117
Although hydrocortisone plus chlorpheniramine or
epinephrine may reduce the risk of adverse reactions,
these were studied with nonovine antivenom formu-
lations that were associated with significantly higher
rates of anaphylaxis.118,119 Pretreatment for the prophy-
laxis of allergic reactions should be given to patients
who have had prior allergic reactions to antivenom and
should be considered for patents with a history of
asthma, atopy, or multiple allergies. (Recommendation
grade: 1B)
CRITICALLY ILL PATIENTS
For the severely ill patient, supportive treatment and
antivenom are the mainstays of therapy. Vasodilation,
capillary leak, third-spacing, or hemorrhage can lead to
hypotension and shock that necessitate supportive fluids.
Fluid replacement with intravenous crystalloid boluses
should be initiated in concert with antivenom dosing
because antivenom remains the definitive treatment.120 If
hypotension persists despite antivenom and fluid therapy,
vasopressor medications are recommended for hemo-
dynamic support. (Recommendation grade: 1B)
Neurotoxic symptoms from species such as C scutu-
latus can be profound; however, antivenom has rela-
tively poor efficacy in reversing presynaptic neuro-
toxicity. That is especially true in patients presenting
late with paralytic features, with ptosis being an early
WMS Practice Guidelines for Pitviper Envenomations 483sign.6 Patients with paralytic features should be carefully
evaluated and intubated or ventilated early, as clinically
indicated, as that can be life saving. (Recommendation
grade: 1C)
Acute renal failure due to rhabdomyolysis can be
treated with standard methods of aggressive fluid hydra-
tion, alkalinization of the urine, and dialysis, if
needed.121 (Recommendation grade: 1C)
Respiratory compromise (unrelated to anaphylaxis) was
found in as many as 8% of critically ill patients after
envenomation, with 4% requiring mechanical ventilation
for airway support.122 (Recommendation grade: 1B)
Blood product transfusion (including packed red blood
cells, fresh frozen plasma, cryoprecipitate, and platelets)
may help maintain normal hematocrit in the case of
severe bleeding; however, unlike antivenom, transfusion
does not reverse or improve coagulopathies. Therefore,
antivenom should be given initially and considered the
mainstay of therapy, with transfusions reserved for only
severe life-threatening hemorrhage or anemia refractory
to antivenom treatment.123 (Recommendation grade: 1C)
Rare and unexpected complications of snakebite enve-
nomations have been documented in the literature. There
has been a case report of a hypercoagulable state with
multiple pulmonary emboli that followed an initial hypo-
coagulable state with hypofibrinogenemia.124 Several case
studies have presented cases of envenomation in which
thrombocytopenia did not improve in a linear fashion with
increasing dosing of antivenom.125 Two cases of
catastrophic ischemic stroke have been reported after
Crotalidae polyvalent immune Fab (ovine)-treated rattle-
snake envenomation.126 A review of the literature
revealed a rate of 0.5% of crotaline envenomations
treated with antivenom that had medically significant
late sequelae requiring rehospitalization, such as
bleeding requiring blood transfusions,127 and 1 case
resulting in death.128 An investigational Crotalidae
equine immune F(ab’)2 antivenom not yet commer-
cially available has shown promise in reducing the risk
of such subacute coagulopathies and bleeding.129 If such
bleeding complications are encountered, repeat dosing
of antivenom may be necessary. (Recommendation
grade: 2C)Summary
Pitviper envenomations can cause significant morbidity
and mortality and must be treated with prompt evidence-
based management protocols. Crotaline envenomations
often produce local tissue injury and swelling and may
result in systemic effects (including coagulopathy, neu-
rotoxicity, or hypotension), the progression of which can
be halted with prompt administration of antivenom.More severe envenomations feature extensive local
effects and life-threatening systemic derangements that
require repeated dosing of antivenom and closely moni-
tored supportive care. Frequent patient assessment and
diligent tracking of progressive signs and abnormal
laboratory results are important for appropriate snakebite
management. Consulting a toxinologist or poison control
center can greatly assist in patient management. Finally,
these guidelines are for crotaline snakes in the United
States and Canada, and cannot be safely extrapolated to
other snakes species or geographic regions.References
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